ROCHE HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.66 USD | -2.56% |
|
-1.59% | -4.33% |
| Jun. 25 | Halozyme Therapeutics Says Roche's OCREVUS SC With ENHANZE Gets European Commission Approval | MT |
| Jun. 25 | Roche: approval of Ocrevus SC in Europe | CF |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 815B | ||||||
| 654B | ||||||
| 354B | - | - | - | - | ||
| 337B | ||||||
| 302B |
